Theophylline ER 450 mg study design [Design Issues]

posted by Ramesh Ramalingam  – India, 2018-10-18 07:16 (1401 d 03:14 ago) – Posting: # 19463
Views: 1,721

Dear Members,

Based on literature reference, Theophylline is a narrow therapeutic index drug. As per USFDA recommendation if the drugs falls under narrow therapeutic index, the BE study should be a fully replicated crossover design in order to:
• Scale bioequivalence limits to the variability of the reference product; and
• Compare test and reference products within-subject variability.

But respective molecule OGD (which was issued on 2010) Draft guidelines recommending two-way cross-over study design.

Could you please suggest the study design whether it should be two-period, two-way crossover design or four period, fully replicated design.


Regards,
Ramesh

Complete thread:

UA Flag
Activity
 Admin contact
22,305 posts in 4,668 threads, 1,587 registered users;
online 7 (0 registered, 7 guests [including 5 identified bots]).
Forum time: Friday 10:31 CEST (Europe/Vienna)

Doctors are men who prescribe medicines of which they know little,
to cure diseases of which they know less,
in human beings of whom they know nothing.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5